

PROSTATE CANCER FOUNDATION



CURING TOGETHER

URO TODAY GU ONC TODAY 20+ years
Partnering with the Prostate Cancer Foundation

A large, semi-transparent blue globe with a white grid of latitude and longitude lines is centered in the background. The globe is partially obscured by a dark blue horizontal band containing the main title.

CHANGING THE WORLD & CURING TOGETHER

30 YEARS OF PROGRESS
HOW PCF HAS CHANGED THE WORLD

Su guía para el
cáncer de próstata

2023-24 Progress Report

Cancer Foundation

This year's annual report documents how PCF has evolved over the last 30 years; including our foundational commitment to funding over 1,000 medical studies worldwide. As a result, PCF has become the world's largest philanthropic funder of prostate-cancer research.

Michael Milken
Founder of The Prostate Cancer Foundation (PCF)

PROSTATE CANCER FOUNDATION



2023-24 Progress Report



Mission Statement:

The Prostate Cancer Foundation (PCF) funds the world's most promising research on the biology and treatment of prostate cancer, accelerating those discoveries into therapies and strategies designed to improve the quality of life and overall survival of patients. PCF is committed to bringing together patients, researchers, caregivers, and clinicians into a singular community focused on reducing death and suffering from this disease.

Thirty years ago, PCF set out on a mission to redefine the landscape of prostate cancer research funding. At the time, understanding of this disease was limited and advocacy efforts were sparse. Scarcity of investment not only impeded scientific advancement, but also marginalized researchers, stifling collaboration. Within this bleak environment, PCF emerged as a catalyst for change. Today, the PCF community stands as a beacon of hope, ushering in an era where patients find strength in unity, cherish every moment with loved ones, can access effective treatments, and aspire to create legacies that transcend their prostate cancer diagnosis.

There are several risk factors, including family history, age, and race. Know your risks and talk to your doctor about early detection and screening.



PCF's Charity Navigator score is 100%, earning it a Four-Star rating.



give.org
PCF meets all 20 of the Better Business Bureau's standards for charity accountability.



PCF has been designated a Top-Rated Charity by Charity Watch

Table of Contents

<i>30 Years of Progress: Supporting Patients and Researchers</i>	5
<i>A message from our President and Chief Science Officer</i>	
<i>Who We Are, What We Do, and Why We Do It</i>	7
<i>Changing the World and Curing Together</i>	10
<i>How PCF has changed the world over the last 30 years</i>	
<i>PCF Commemorates 30 Years of Life-Saving Effort</i>	14
<i>Science: Empowering a Research Community</i>	19
<i>Forging Ahead: FDA Approves PCF-Funded Therapy for Advanced Prostate Cancer</i>	20
<i>Young Investigator Awards Program</i>	21
<i>PCF Celebrates the 30th Annual Scientific Retreat</i>	23
<i>Pushing Out The Frontiers: Jim Allison’s Story</i>	25
<i>PCF’s Partnership with the Veterans Administration</i>	27
<i>Digital Science Press / UroToday</i>	29
<i>Patients: The Power of Education</i>	31
<i>Tom’s Story: The Impact of Prostate Cancer on Other’s Lives</i>	32
<i>Another Year Around the Bases for the 2023 Home Run Challenge</i>	34
<i>PCF Webinar Series 2023-2024</i>	35
<i>Patient Highlights</i>	36
<i>Patient Community and Educational Initiatives</i>	37
<i>Prostate Cancer Patient Voices: new patient testimonial website</i>	38
<i>PCF’s Mission to Improve Health Equity</i>	39
<i>Five Reasons to Invest in PCF</i>	41
<i>Harnessing Relationships and Passion to Fund Crucial Research</i>	44
<i>PCF 2023 Consolidated Financial Statements</i>	46
<i>Board of Directors and Leadership Team</i>	52

30 Years of Progress: Supporting Patients and Researchers

Dear Friends,

Thanks to your support of the Prostate Cancer Foundation, we've made major strides against prostate cancer and helped millions of men live full lives with the disease today. If you—like nearly one and a half million Americans each year—have ever been told, 'you have cancer,' you know that you will always remember that moment. Whether you are a patient, family member, or friend, ***we welcome you to our community***. We're grateful you're here to join us in the fight against prostate cancer.

There has never been a brighter time in the history of medicine for speeding breakthroughs to patients with prostate cancer. PCF has identified four key opportunities to build on our progress and further reduce death and suffering from this disease:

- 1. Fund research** on prostate cancer biology and treatment.
- 2. Identify and close gaps** in treatment implementation.
- 3. Drive better patient outcomes** by improving prostate cancer awareness, screening, and early detection.
- 4. Promote a healthy lifestyle** for patients through a nutritious diet and exercise.

To support these priorities, we launched new initiatives last year which already are producing exciting outcomes. Among the highlights:

- **The U.S. Food and Drug Administration (FDA) approved a new first-in-class therapy** for patients with metastatic treatment-resistant prostate cancer. Lutetium Lu 177 vipivotide tetraxetan, or **177Lu**, (brand name **PLUVICTO®**) targets PSMA, a protein on the surface of prostate cancer cells. This approval marks the culmination of decades of PCF involvement — in all, we've invested **over \$28 million** in research on PSMA, helping define it as a unique, opportune, and effective therapeutic target.
- **Our new TACTICAL (Treatment ACceleration To Intercept CAncer Lethality) research award program**, PCF's largest and boldest grantmaking program ever, propels our proven 'Team Science' model to the next level. Our TACTICAL program focuses solely on the development of new prostate cancer therapies by building on recent success in identifying key drivers of treatment resistance and lethality. PCF recently funded five new teams of researchers worldwide who are conducting large-scale, multi-year projects and together represent more than 10 institutions. This is 'Team Science' at its best—we expect great progress from this program.
- **PCF launched new, broad-ranging communications through our partnership with Digital Science Press**. We now **host monthly patient webinars** on **[PCF.org](https://www.pcf.org)** and in 2022, convened our first-ever **Prostate Cancer Patient Summits** in Milwaukee and New Orleans. In 2023, we successfully hosted **two additional patient summits** in Chicago and Milwaukee. We look forward to hosting our 2024 summits virtually! You can now find **hundreds of new**

informational videos at [PCF.org](https://www.pcf.org) and at our partner site, [UroToday.com](https://www.UroToday.com), covering the latest news and progress in the field. These heightened communication efforts will enable timely information to reach patients, families, researchers, and clinicians around the world, enhancing PCF's impact on the prostate cancer community.

Meanwhile, you will note in these pages that **2023 marked PCF's 30th anniversary!**

PCF was founded in 1993 with a core mission of keeping a prostate cancer diagnosis from being a death sentence. Thanks to our efforts over the past 30 years, **average survival for men with hormone-resistant prostate cancer has risen from approximately 11 months to well over four years**, with some exceptional responders living much longer. We can celebrate the fact that 30 years after our founding, **our mission now includes promoting high-quality survivorship**: The fact that patients are living longer with prostate cancer creates opportunities to help them live well during and after treatment.

Today, thanks to PCF-funded discoveries that have spurred advances in precision medicine, treatment pathways, guidelines, and imaging modalities, outcomes have improved significantly not only in prostate cancer, but in many other cancers, too. Undoubtedly, however, more challenges lie ahead. Too many of our loved ones are still being diagnosed with prostate cancer or die from the disease each day.

None of PCF's work would be possible without a community that includes **you**. We do our work so that you and your loved ones can live longer and better. **Thank you** for choosing to join the PCF community — we are stronger for it.

Together, we will advance our work to reduce the impact of prostate cancer.

With best wishes to you and your family,



Howard Soule, PhD
Chief Science Officer & Interim CEO




Gina Carithers
President



P.S. Should you have the means and inclination to help support our life-saving research, please visit our website at [pcf.org/donate](https://www.pcf.org/donate) to make your tax-deductible gift.

Who We Are —

PCF is the world's leading philanthropic organization dedicated to funding life-saving prostate cancer research. Founded in 1993 by Mike Milken, PCF has helped raise nearly \$1 billion to support more than 2,200 cutting-edge research projects at 245 leading cancer centers in 28 countries around the world.



What We Do —

- *Identify the most promising ideas from teams of top scientists and brilliant young researchers early in their careers.*
- *Fund programs efficiently and effectively.*
- *Create community among the PCF family of researchers to inspire collaboration and synergy of ideas.*
- *Empower patients and their loved ones with the knowledge they need to make decisions about their care.*

Why We Do It —

- *In 2024, an estimated 299,020 U.S. men will be diagnosed with prostate cancer. That is one new case every two minutes.*
- *More than 35,000 men are projected to die of the disease this year.*
- *Globally, 1.4 million men are diagnosed per year.*
- *The burden is not borne equally: 1 in 6 Black men will develop prostate cancer in his lifetime (vs. 1 in 8 white men), and Black men who are diagnosed are more than twice as likely to die.*





2,250

RESEARCHERS FUNDED

500

YOUNG INVESTIGATORS

24.5

CANCER CENTERS

28

COUNTRIES

PCF's Impact over 30 years


1993

- More than 1 in 6 men were diagnosed with prostate cancer in their lifetime.
- In the U.S., prostate cancer claimed more than 40,000 lives annually.
- Because of population aging, these numbers were projected to get much worse.
- Only three drugs were FDA-approved for prostate cancer treatment.
- Late-stage diagnosis was the norm: 70% of patients were diagnosed only after developing advanced symptoms such as bone pain.

2023-24

- About 1 in 8 men are diagnosed with prostate cancer in their lifetime.
- In the U.S., there are about 5,000 fewer prostate cancer deaths annually than in 1993.
- Today's prostate cancer death rate is 80% lower than what experts projected 30 years ago.
- 27 drugs are FDA-approved for treating prostate cancer, and over half were developed with PCF support.
- Early detection is the norm: Most men are diagnosed by routine screening, and less than 5% present with incurable disease.

PCF's RESEARCH IMPACTS MULTIPLE CANCERS, INCLUDING:



- Brain
- Eye
- Lip
- Neck
- Thyroid
- Esophagus
- Thymus
- Lung
- Liver
- Stomach
- Gallbladder
- Pancreas
- Kidney
- Colon
- Bladder
- Rectum
- Skin
- Nerve
- Blood
- Sarcoma
- Prostate
- Testicle
- Breast
- Cervix
- Ovary
- Uterus
- Childhood Brain Cancer
- Childhood Blood Cancer
- Childhood Kidney Cancer
- Others

30 Years of Impact

- More than \$1 billion raised for prostate cancer research.
- Funding for more than 2,250 research programs at over 245 cancer centers and universities worldwide.
- Support for the early development of 14 new prostate cancer therapies, plus countless studies to help identify which treatments can benefit which patients.
- Creation of a new model for streamlining and accelerating groundbreaking medical research.

2,250

RESEARCH PROGRAMS
FUNDED

245

CANCER CENTERS & UNIVERSITIES
FUNDED WORLDWIDE

14

NEW PROSTATE CANCER THERAPIES
FUNDED IN EARLY DEVELOPMENT.




**Prostate
Cancer
Foundation
30 YEARS**
Curing Together.



1993
CAP CURE FOUNDED

In 1993, Mike Milken lays the foundation for PCF by establishing Cap CURE, which aims to spur medical research in the vastly underfunded field of prostate cancer. From a landscape once marked by dismal prospects for patients with advanced disease, PCF-backed scientists will go on to catalyze the development of nearly a dozen FDA-approved therapies, ultimately prolonging and improving countless lives worldwide.

Today, PCF-funded projects span 28 countries, leaving an indelible mark on cancer research across the biomedical landscape.



1996
*HOME RUN CHALLENGE:
28 YEARS STRONG*

In 1996, Mike Milken and MFF Trustee Rosey Grier team up to create the Major League Baseball-PCF Home Run Challenge, which is held annually around Father's Day. With help from supporters like MLB owners Peter McGowan, Jerry Reinsdorf, and Fred Wilpon, each home run hit during Home Run Challenge games raises funds for prostate cancer research. Participants include dozens of active players and more than 100 All-Stars, including Hall of Famers like Willie Mays. Together, they have hit nearly 5,000 home runs, raising close to \$80 million for prostate cancer research.



1996

CAP CURE BOARD OF DIRECTORS MEETING

Also in 1996, PCF completes its fourth cycle of competitive award applications, granting \$7 million to 73 researchers at 38 institutions, including five outside the U.S. Just three years previously, almost all awards had funded basic laboratory research. In 1996, 50 projects have near-term or immediate clinical applications. The same year, PCF establishes the PCF Therapy Consortium, a seven-center cooperative project formed to accelerate clinical trials of promising agents. This collaboration lays the groundwork for the Prostate Cancer Clinical Trials Consortium, which remains the preeminent prostate cancer clinical trials network today.



1997

***JAMES ALLISON, PhD:
SUPPORTING IMMUNOLOGY***

Michael and Lori Milken's financial backing sustains Dr. James Allison's Berkeley laboratory, enabling him to keep conducting pioneering research on cancer metastasis and immune response inhibition. Supported by PCF, Dr. Allison's efforts lead to the development of revolutionary checkpoint-inhibitor drugs like ipilimumab (YERVOY®), pembrolizumab (KEYTRUDA®), and nivolumab (OPDIVO®). Dr. Allison's remarkable achievements later earn him the Nobel Prize in Medicine 2018.



1998

THE MARCH ON WASHINGTON

On September 25-26, 1998, The March: Coming Together to Conquer Cancer takes place in Washington, DC. Organized by Cap CURE, the march is the culmination of 5 years of dedicated effort. Hundreds of thousands of people representing 600 organizations and medical centers gather on the National Mall to voice their support for cancer research and treatment. Distinguished speakers, including Vice President Al Gore and PCF Founder Michael Milken, inspire hope and unity. The March spurs Congress to double funding for the National Institutes of Health (NIH) to advance the fight against cancer.



2000

*FRANCIS COLLINS, MD, PhD:
DECODING THE HUMAN GENOME*

After more than a decade of relentless effort, Dr. Francis Collins leads 2,400 researchers in completing the first draft of the human genome, a landmark achievement that provides unprecedented insights into humanity's genetic blueprint. Dr. Collins' exceptional leadership on this project propels him to become the 16th director of the NIH. During his 2009-2021 tenure, the NIH continues to drive groundbreaking research and innovation, significantly impacting the biomedical sciences.



2011

*LAKE TAHOE
INNOVATION RETREAT*


PCF joins the Lake Tahoe Innovation Retreat, which convenes experts across many fields to brainstorm advances in medical innovations. Experts propose redefining risk, supporting young researchers, and streamlining research and therapeutic development pipelines. In addition, they advocate for a new entity within the NIH to improve translational science. Mike Milken later persuades Congress to establish the National Center for Advancing Translational Sciences (NCATS), which President Obama signs into law the following year.



2012

*INTERNATIONAL EAST COAST /
WEST COAST DREAM TEAMS*

In 2012, PCF raises \$20 million from various philanthropists and organizations to launch two Dream Teams to advance prostate cancer research by analyzing large-scale molecular datasets. Overseen by PCF Chief Science Officer Howard Soule, PhD, these innovative teams together include more than 113 scientists in the U.S., the United Kingdom, and Canada and collectively assess genomic profiles from 750 patients with advanced prostate cancer. To accelerate their work, the teams share data regularly and report on their progress every six months.



2012 CELEBRATION OF SCIENCE

PCF and the Milken Institute's Faster Cures Center host 'Celebration of Science,' which gathers senior Congress members, Obama Administration representatives, and over 1,000 leaders in bioscience and related fields. The event highlights the importance of the biosciences and inspires bipartisan commitment to increase NIH funding. More than 25 years after the 1998 March on Washington, Congress allocates approximately \$500 million in additional funds for NIH research, reaffirming federal support for the medical sciences and public health.



2016 PCF & VA PARTNERSHIP

The U.S. Department of Veterans Affairs (VA) partners with PCF in a \$50-million collaboration aimed at providing precision oncology treatments for all veterans with prostate cancer by 2023. The PCF-VA partnership utilizes the VA's extensive health database, effectively doubling its cancer research portfolio. In all, 14 PCF-VA Centers of Excellence are established nationwide, propelling innovative medical research and supporting personalized treatment based on tumor gene and molecular testing. By ensuring top-tier care for every veteran, the partnership significantly reduces disparities in prostate cancer survival rates among men of African ancestry within the VA patient population.



2022 MILKEN INSTITUTE GLOBAL CONFERENCE: 25 YEARS

For the 25th time, the Milken Institute Global Conference convenes the world's top thought leaders, policymakers, and experts for four days of insights and connection at the Beverly Hilton Hotel in Beverly Hills. After 2 years of social distancing due to COVID, 2022's theme was, appropriately, 'Celebrating the Power of Connection.' More than 3,500 guests attend hundreds of sessions organized under 13 core content tracks, including Business and Industry, Philanthropy and Social Impact, Capital Access and Economic Opportunity, Society and Culture, Financial Markets, Health and Medical Research, and others.




TOP 30 in 30

PCF 30th Anniversary Impact

How PCF has made a life-saving impact on prostate cancer

1 Since PCF's founding in 1993, the death rate from prostate cancer has been **cut in half**.



2

PCF has **raised over \$1 billion** for prostate cancer research to save and extend patients' lives.

3

PCF has contributed to a **20-fold increase in government funding** for prostate cancer research over the past 30 years.




4

Approximately **1.4 million prostate cancer deaths have been averted** since PCF's founding in 1993.

5

Our work applies to the entire cancer spectrum. Thanks to advances in precision medicine, PCF-funded discoveries now impact patterns, pathways, and processes that drive not only prostate cancer, but many other cancers as well.



6

PCF has **funded almost every practice-changing development in prostate cancer** in the last 30 years.

7

We continue to work to keep more families whole. Without new treatments, nearly 35,000 men are projected to lose their battle with prostate cancer this year.



TOP 30 in 30

PCF 30th Anniversary Impact

How PCF has made a life-saving impact on prostate cancer

8

PCF was **one of the first scientific foundations to invest in research on lifestyle changes to improve health, including nutrition and exercise**, both of which we now know to be incredibly important for cancer prevention and recovery.




9

Between 2000 and 2024, PCF funded **early-stage research for 14 FDA-approved, life-extending prostate cancer treatments**, with many more under investigation today.

10

In 2016, PCF **partnered with the VA to help shepherd extraordinary care for the more than 15,000 veterans diagnosed with prostate cancer annually.**



11

We give millions of dollars in grants to the best and brightest in the field. In all, we have granted **232 Challenge Awards and 407 Young Investigator Awards** to date.




12

We were also one of the first cancer research organizations to fund studies of immunotherapies: groundbreaking treatments that harness a person's own immune system to fight their cancer.

13

PCF's **global funding engine** has supported more than 7,000 scientists involved in 2,250 projects at more than 245 cancer centers and universities in 28 countries.



TOP 30 in 30

PCF 30th Anniversary Impact

How PCF has made a life-saving impact on prostate cancer

- 14** The **MLB-PCF Home Run Challenge**, which directly supports PCF, is the longest-running philanthropic pro sports league partnership in history.



- 17** PCF has consistently advocated for women in science and has supported young women in the early stages of their careers through the Young Investigator Award Program.



15

PCF has sped up development of life-saving therapies by eliminating the administrative hurdles imposed by most other research funders, encouraging collaboration among researchers, and requiring PCF researchers to share results with one another. These actions have created an HOV lane for drug development.

16

PCF is part of the largest single cohort study to **research and rectify disease disparities in men of African descent**.




18

PCF's guides, webinars, and summits empower patients and families with the knowledge they need to make decisions about their care.

19

PCF was one of the **original funders of research on solid tumor CAR T-cell therapy**, a powerful immunotherapy in which a patient's own T cells are engineered to recognize and kill their cancer.



TOP 30 in 30

PCF 30th Anniversary Impact

How PCF has made a life-saving impact on prostate cancer

20 **Researchers funded by PCF have gone on to win Nobel Prizes for their work.** PCF was an early funder of projects by 2004 Nobel Prize in Chemistry laureate Dr. Aaron Ciechanover, 2018 Nobel Prize in Medicine laureate Dr. James Allison, and 2022 Nobel Prize in Chemistry laureate Dr. Carolyn Bertozzi.



23 **PCF fosters a supportive community for patients with prostate cancer and their loved ones.** Our support groups and virtual events offer a unique and inspiring platform where individuals who have faced this battle can connect and empower each other.



24 **PCF provides the best life insurance.** We identify and fund the most promising ideas from teams of top scientists around the world and support brilliant young researchers early in their careers.

25 **PCF was an early adopter of the use of big data to tackle cancer.** For example, we funded a data-sharing platform that enabled scientists to exchange information about genetic abnormalities that may overlap in many cancers.



21 **PCF has spearheaded a culture of collaboration** in a field notorious for competition by requiring all our funded researchers to share their data to help accelerate treatments.

22 **PCF's inaugural TACTICAL Awards (Treatment ACceleration To Intercept Cancer Lethality) push 'Team Science' to the next level** by supporting multi-year, large projects that aim to develop new treatments for the most life-threatening forms of prostate cancer.

TOP 30 in 30

PCF 30th Anniversary Impact

How PCF has made a life-saving impact on prostate cancer

26

Patient care drives PCF's mission.

Our patient-centric research support revolves around the **'three P's'**: **preserving function**, quality of life and activity level in advanced prostate cancer, **preventing pain**, hospitalizations, and health decline, and **prolonging life**.



27


PCF helps men with prostate cancer live **longer, fuller lives** by relentlessly advocating for precision screening, active surveillance, education, and alternatives to hormone therapy and chemotherapy.

28

Thanks to PCF, average survival for men with **hormone-resistant prostate cancer** has more than quadrupled from only about 11 months when we were founded in 1993 to well over four years today, with some exceptional responders living much longer.

29

PCF works not only to keep men healthy and free of prostate cancer, but to **keep the whole family safe**. We fund genetic studies of many tumor types to help identify cures for breast cancer, colon cancer, ovarian cancer, and more.



30

With enough funding, we project that we can **end 99.9% of all deaths from prostate cancer** within 20 years.

Science: Empowering a Research Community



The contribution, or loss, of even the greatest researcher isn't likely to make or break the future of a cancer cure. That role belongs to the community of great research institutions—repositories of accumulated intellectual, physical and financial resources that represent the 'social capital' of medical progress. I've seen the Prostate Cancer Foundation live up to its name—as a foundation—by laying the cornerstone for at least three major social capital initiatives involving this community.

Howard R. Soule, PhD
Chief Science Officer / Interim CEO, Prostate Cancer Foundation

1. Collaboration

PCF's impact on clinical research is evident in its collaboration with the U.S. Department of Defense to establish 13 clinical investigation centers, known as the Prostate Cancer Clinical Trials Consortium. Formed to address critically unmet needs in prostate cancer research, PCCTC today includes 13 prestigious research institutions—Dana-Farber Cancer Institute, Duke University, Johns Hopkins University, Memorial Sloan Kettering Cancer Center, and others. This consortium has significantly influenced the funding and execution of clinical work. As of 2024, 27 therapies have been approved by the FDA for the treatment of prostate cancer, with even more in the pipeline.


2. Teamwork

PCF has pioneered a shift in research funding away from competition and towards collaborative teamwork. By bringing together scientists with diverse expertise, our grants address significant challenges in prostate cancer biology and treatment. While we initially focused on individual research awards, we have transitioned toward funding team-based science to maximize our funding impact by fostering synergistic collaborations among researchers.

3. Integrating Academic & Industry Science

PCF has revolutionized prostate cancer research by integrating academia and industry. During PCF's early years, most participants hailed from academic institutions, and very few pharmaceutical companies were involved. Today, nearly all major pharmaceutical and biotech companies attend and report their progress at our annual meetings. This has fueled the development of numerous new drugs that are available to patients today.

FDA Approves First-in-Class PCF-Funded Therapy for Advanced Prostate Cancer



*In March 2022, the FDA approved lutetium-177 vipivotide tetraxetan (Pluvicto®) based on the results of the randomized, international, phase 3 VISION trial, led by PCF-funded investigators **Michael J. Morris, MD of Memorial Sloan Kettering Cancer Center (right) and Oliver Sartor, MD of Mayo Clinic (left).***

Radioligand therapies are a new class of treatments consisting of a tumor-targeting molecule attached to a radioactive isotope. This innovation enables cancer-killing radiation to be delivered directly to tumors anywhere in the body while sparing normal tissue.

Lutetium Lu 177 vipivotide tetraxetan (Pluvicto®), previously known as 177Lu-PSMA-617) is a **first-in-class radioligand therapy** that specifically targets **PSMA**, a protein found on the surface of most prostate cancer cells that is absent on most normal cells.

Lutetium Lu 177 vipivotide tetraxetan is currently approved for use in patients with PSMA PET-positive, metastatic castration-resistant prostate cancer (mCRPC) who have already received an

androgen receptor pathway inhibitor and taxane chemotherapy.

PSMA PET is a highly sensitive next-generation imaging technology that can detect metastatic prostate cancer even in the early stages. By using PSMA PET, clinicians can determine which patients are likely to benefit from PSMA-targeted radioligand therapies and monitor how they respond over time.

Since 1993, PCF has invested over \$40 million in research on PSMA. Multiple trials led by PCF-funded investigators are currently testing PSMA-targeted radioligand therapies in different stages of prostate cancer.

PCF's new TACTICAL Awards initiative is specifically designed to further advance progress on this front.

This approval is another major success for patients made possible by PCF's unique, visionary research-funding strategy and our community's early recognition of PSMA's potential as a therapeutic and imaging target.

Young Investigator Awards



PCF Young Investigators make prostate cancer one of the most promising areas of cancer research for patients and scientists by delivering advances that will help ‘cure more and over-treat less.’ Our Young Investigators are the best and brightest in their fields—early-career researchers who usually have achieved junior faculty positions, have demonstrated innovation and leadership, and have shown a strong commitment to prostate cancer research.

The Young Investigator Awards program provides significant professional and project support for recipients. Each awardee receives a three-year grant comprising a total of \$300,000, which is matched dollar-for-dollar by their university. In addition, each awardee is mentored by 1-3 senior investigators who are well recognized in their field.

The Young Investigator Awards program dates to 2007, when we launched ‘PCF 100’ to secure support for 100 Young Investigators. Since then, PCF has invested more than \$84 million in Young Investigator Awards to support future research leaders who will keep the field of prostate cancer vibrant with new ideas. Young Investigators also ‘pay it forward,’ building a foundation of knowledge upon which future generations can expand and providing mentorship that guides and inspires that work.

“Supporting a focus on prostate cancer by [funding] talented young investigators is critical to realizing PCF’s goal of accelerating breakthrough discoveries that can potentially end death and suffering from prostate cancer.”

Howard R. Soule, PhD

Chief Science Officer & Interim CEO | Prostate Cancer Foundation

Young Investigators Over the Years



PCF Celebrates the 30th Annual Scientific Retreat



The Annual Prostate Cancer Foundation Scientific Retreat is the preeminent global conference dedicated to the biology and treatment of prostate cancer. Its unparalleled diversity, novelty, and high-impact presentations, coupled with the exceptional caliber of attendees, make it a truly unique gathering. Reflecting PCF's steadfast commitment to ending prostate cancer's toll, the Scientific Retreat cultivates a collaborative ethos that is unmatched in cancer research, propelling breakthroughs in understanding and treatment.

Since its inception in 1993, PCF has annually convened this Scientific Retreat to unite diverse researchers in a cooperative forum. Celebrating its 30th year, the 2023 Retreat, held October 26–28 at the Omni La Costa Resort in Carlsbad, CA, epitomized this tradition. Leading scientists, clinicians, and interdisciplinary experts exchanged cutting-edge research findings and ideas and explored emerging directions. For the second consecutive year, the event also adopted a hybrid format, allowing remote participants to engage in real time and present virtual posters.

Recognized as a pinnacle in prostate cancer research, PCF's Annual Scientific Retreat continues to drive understanding and accelerate therapeutic development. Its diverse scientific lectures, panel discussions, poster sessions, and interactive events make it a hallmark of innovation and collaboration.

The 30th Annual PCF Scientific Retreat featured the following:

934

Individuals from
25 countries registered

621

Academic researchers /
healthcare professionals

285

Biopharmaceutical
industry professionals

145

Academic institutions

33


Different prostate cancer
research disciplines presented.

PCF Celebrates the 30th Annual Scientific Retreat



Pushing The Frontiers

Below is an excerpt adapted from
Faster Cures: Accelerating the Future of Health



James P. Allison, Recipient of the Nobel Prize in Physiology or Medicine 2018

Jim grew up in the small town of Alice, Texas, less than two hours by car from the Mexican border. The 1957 Sputnik launch fueled his interest in science. Thanks to Sputnik, the University of Texas offered summer programs in science for high school students.

Jim started college as a pre-med major at age sixteen. Between listening to the music of Willie Nelson and sneaking down to Mexico with his buddies to hang out in bars, he sometimes went to classes. At first, he thought he might follow in the footsteps of his father, a country doctor who treated patients in the Hispanic part of town where they lived. Eventually, he gravitated towards science. Jim once told me why he didn't go into medicine: "MDs fill their heads with facts they've memorized and then draw on those facts in treating patients. They're always supposed to be right. What I love about science is that it isn't about

memorizing and trying to be right; in science, you're supposed to be wrong, which makes it a lot more fun."

When he was still in college, a biology professor mentioned a new discovery called T cells, which attack foreign substances in the body. Not much was known about these cells, and Jim liked the challenge of figuring them out. After years of hard work, he became the first to explain their structure. Several more years in his lab led to the development of checkpoint inhibitors, one of the most exciting breakthroughs in cancer treatment in the past quarter century. This work earned him the 2018 Nobel Prize.

At PCF's 1997 retreat, long before he was well known, Jim said something that changed Mike Milken's entire perspective and mobilized him to focus on immunology. In fact, it was an idea that changed the world. "Your immune system," said Jim, "is smarter than any of us. Disease occurs when it fails."

He explained to [Mike] that there are three reasons people develop cancers:

- **The patient's immune system is weakened by age, lifestyle factors, and comorbidities.** In the majority of cancers, this causes inflammation, which has become a central focus of cancer research.
- **The cancer sometimes disguises itself so it can compromise the body's defenses.** Building on Allison's insight, Dr. Carl June at the University of Pennsylvania later conceived the concept of cellular therapies in which a patient's own immune cells, rather than a donor's, are engineered to destroy cancer. The idea is to energize the immune system by removing T cells from the patient, "teaching" those cells how to recognize the disguised cancer cells, and then returning them to the body in "attack mode." Deploying these chimeric antigen receptors (CAR T cells), Dr. June improved treatments for acute lymphoblastic leukemia, the most common cancer in children. Then, in 2022, the FDA approved Johnson & Johnson's CAR T-cell treatment for another blood cancer, multiple myeloma. In J&J studies, 83% of patients who received CAR T-cell therapy experienced complete remission and had no detectable cancer cells. PCF has funded Dr. June's work for many years.
- **The cancer turns off the immune system.** Allison's greatest triumph may be the development of checkpoint inhibitors that turn the immune system back on by suppressing what had turned it off. In other words, Jim figured out how to block the 'off' switch.

Listening to Jim, Mike Milken decided to fund ongoing research at his Berkeley lab. Helped by PCF's initial grant and other funding, Jim was able to demonstrate the market potential of his "immune system off-switch blocker." After further development, Berkeley received initial payments of more than \$87 million from Bristol Myers Squibb for Allison's antibody. These funds were plowed back into further research.

In 2011, the Food and Drug Administration approved Yervoy®, which had been developed from Allison's work, after clinical trials showed that it dramatically extended survival times for many patients with advanced melanoma. And because today's precision medicine can identify the specific subtype of a tumor anywhere in the body, Yervoy® and similar immunology drugs, such as Keytruda® and Opdivo®, are now being used against several other types of cancer. Millions of people around the world have benefited from the spin-offs of Jim Allison's breakthrough discoveries.

PCF & Jim Allison over the years:



PCF's Partnership with the VA

*Inspired by the Sacrifice and Service of Our Nation's
Military Veterans Fighting Prostate Cancer*



PCF's VA Health Initiative staff and funded researchers gather at the 29th Annual PCF Scientific Retreat.



Mike Milken and Whoopi Goldberg with U.S. military veteran honorees at the 2017 PCF New York Dinner.

In 2022, PCF joined VA leaders as part of the re-ignited national Cancer Moonshot effort, which aims to lessen cancer's deadly impact by improving diagnosis, treatment, and survival. A Cancer Cabinet Community Conversation held at the White House focused on prostate cancer and other GU cancers. This dialogue helped guide Cancer Moonshot's priorities by calling attention to VA patients and providers and raising awareness about prostate cancer's burden on veterans and military families.

PCF's partnership with the VA began in 2016 and was a cornerstone of Cancer Moonshot's work to speed up advances in cancer research. PCF's expertise and track record as the leading funder of prostate cancer research was a natural match for the VA, given the large number of veterans living with this disease.

In addition, PCF's Veterans Health Initiative aims to deliver care to veterans that is as good or better than any private treatment available, while providing a roadmap for the application of cutting-edge precision oncology for all forms of cancer, to benefit everyone.

In its first five years, the PCF-VA partnership focused on precision oncology, a transformative approach that aims to deliver the right treatment to the right patient. Precision oncology utilizes each cancer's unique genetic fingerprint to match patients with treatments, including novel therapies. This personalized approach helps patients with limited treatment options receive targeted therapies.

To advance the mission and scope of this important initiative, PCF partnered with


philanthropists to invest in prostate cancer-focused Centers of Excellence (CoEs) at VA medical centers across the country. Each CoE is affiliated with an academic institution and a National Cancer Institute (NCI)-Designated Cancer Center in a hub-and-spoke model. In this way, VA research can reach and influence medical centers in diverse geographic regions.

In 2022, seven more PCF-VA CoEs were added, bringing the total number of sites to 22. Last year, CoEs provided care for more than 63,000 veterans living with prostate cancer including tens of thousands of clinical visits for veterans with metastatic forms of the disease. Currently, the PCF-VA Network includes more than 200 investigators and healthcare providers who work closely together to promote quality research and avert death and suffering. Their focus also has broadened to include other genitourinary malignancies such as bladder and kidney cancer.

Army Vet David Atkinson & Dr. Julie Graff



David Atkinson, a West Point graduate and U.S. Army veteran, was treated by PCF-funded researcher and medical oncologist Dr. Julie Graff at the PCF-VA Center of Excellence in Portland. When David's prostate cancer didn't respond to standard treatment, Dr. Graff ordered biomarker testing of his tumor to look for gene mutations. Based on the results, she started him on the immunotherapy pembrolizumab. Atkinson is confident in his partnership with Dr. Graff and continues to stay informed of developments in prostate cancer research, saying, "There's something new coming down the pike all the time."



Digital Science Press & UroToday.com

A digital publisher of UroToday.com and a global leader in providing evidence-based clinical content and educational resources within the fields of urology and genitourinary oncology.

Founded in 2003 by Gina B. Carithers, UroToday is a leading educational resource in urology, specifically genitourinary (GU) oncology. UroToday now reaches millions globally, providing free, accurate, timely, evidence-based content that helps medical professionals stay fully informed about dynamic advances in improving patient outcomes. The UroToday platform offers content from expert oncologists, urologists, and other healthcare providers, data from academic conferences, and training videos, interviews, and a clinical trials database to help clinicians stay abreast of GU diseases and treatments.


“We have been entrusted as the industry leader to keep clinicians and researchers up to date on emerging trends that inform and change practices.”

In 2022, PCF acquired UroToday.com and its parent company, Digital Science Press, Inc. The acquisition enhances PCF’s mission to fund research and improve prostate cancer care through expanded communication channels that benefit patients, clinicians, researchers, and the public.

Gina Carithers remains Digital Science Press’s CEO and in 2023 assumed the role of PCF’s President. Under her leadership, UroToday now serves over 125,000 medical professionals and patients in 202 countries.

Carithers, an internationally recognized healthcare marketing leader with over 20 years of experience in the pharmaceutical industry, has driven UroToday’s growth and innovation. Today, the platform is recognized as one of the most trusted and comprehensive educational resources in urology and GU oncology.

To learn more, visit UroToday.com.



Celebrating 20 Years of:

Disseminating new science

Advancing the field of urology

Improving patient outcomes

Digital Science Press & UroToday.com

URO TODAY® **20+** years GU ONC TODAY™

PARTNERING WITH THE PROSTATE CANCER FOUNDATION
Powering Education Driven by Evidence




Gina B. Carithers

Founder & CEO of UroToday / Digital Science Press, LLC

“UroToday.com captures 98% of urologists and urologic oncologists in the U.S., and we take great pride in our partnership with the Prostate Cancer Foundation. Honored by their support, we remain dedicated to translating scientific knowledge into clinical practice. As the premier healthcare education company, UroToday provides clinicians with free access to information on genitourinary malignancies, advancing the standard of care for patients. Together, we are making a meaningful impact in urology, staying at the forefront of the latest advancements in the field.”

UroToday.com 2023 Year in Review



Patients: Building Community Through Education



“At PCF, our core mission is to empower patients with prostate cancer with the resources they need to navigate their journey effectively. We recognize the confusion and isolation that a prostate cancer diagnosis can entail and are committed to providing patients and their caregivers with accurate information, support, and community. Using a patient-centered approach, we aim to reach individuals where they are, offering hope, awareness, and empowerment. By fostering connections through online communities and initiatives like Prostate Cancer Patient Voices, we strive to ensure that no one faces prostate cancer alone, but instead finds strength and resilience in shared experiences and knowledge.”

Gina Carithers

President, Prostate Cancer Foundation / Founder, UroToday

1. Education

At the core of PCF’s mission is patient centricity—we strive to provide hope, awareness, and empowerment to all individuals affected by prostate cancer. Recognizing the confusion and isolation that often accompany a diagnosis, PCF is dedicated to empowering patients and their loved ones with accurate knowledge and resources so they can make informed decisions about their care. This commitment is reflected in a range of educational initiatives, including comprehensive patient guides, expert-led webinars exploring various aspects of diagnosis and treatment, and virtual summits that connect patients with survivors and healthcare providers. Regular updates on PCF.org ensure access to the latest research findings and practical health advice, reinforcing our commitment to supporting patients throughout their prostate cancer journey.

2. Community & Support

PCF’s Facebook support groups and virtual run/walk challenges not only raise awareness about prostate cancer but also provide a nurturing way for participants to share experiences and offer one another crucial support. By cultivating these compassionate, inclusive communities, PCF helps patients and their loved ones access vital support all along the prostate cancer journey.

3. Sharing Stories

We’re excited to announce our collaboration with UroToday on our latest patient initiative, Prostate Cancer Patient Voices. This platform was born from insights gathered during live patient summits, where we listened closely to the needs of patients living with prostate cancer. Prostate Cancer Patient Voices aims to empower men by providing a platform where they can share their stories and experiences. By centering personal narratives, the platform creates a community where patients and loved ones can learn, inspire, and empower each other to navigate prostate cancer confidently and live well with the disease.



A Patient Story: Tom Hulsey

“The Impact on Other Lives”

Survivor and advocate Tom Hulsey wants other men to know that they don't have to go through prostate cancer alone.

Tom Hulsey has been an endurance athlete for more than 40 years and has completed too many races to count. When he learned he had prostate cancer, he did not let that stop him from lacing up his running shoes and getting back on his bike. (In fact, he trained for a half-distance Ironman Triathlon in Hawaii earlier this year.) But for Tom, it is no longer about finishing a race. It is about getting to the starting line and using his platform to share his experiences and help other men facing a prostate cancer diagnosis.

Tom is guided by one of Jackie Robinson's quotes: “A life is not important except for the impact it has on other lives.” Through his work on awareness and advocacy, he aims to forge connections, break the silence and stigma surrounding a cancer diagnosis, and increase funding for prostate cancer research.

Isolated and overwhelmed

Because his grandfather had died of prostate cancer, Tom was aware of his increased risk and received regular PSA screenings. The first time his PSA was up, he and his urologist decided to monitor it, but after two more increases, he received a biopsy. His diagnosis came in 2015 on his 61st birthday. The cancer was graded as Gleason 7 and confined to the prostate—meaning his prognosis was good.

Still, the word cancer came as a complete shock. Tom had always been very fit. “I felt like Superman,” he recalls. “Cancer was the farthest thing from my mind.” Normally an outgoing, open person, he retreated, telling almost no one about his diagnosis and feeling overwhelmed, angry, and embarrassed. Fortunately, even as Tom struggled emotionally, he was able to research his treatment options and consult with specialists about surgery, external beam radiation therapy, and brachytherapy. He also recognized that many other men were dealing with their own diagnosis in isolation.

Setting small goals

Setting goals had always been crucial to Tom's success as an athlete. Now, he found that working towards short and long-term goals changed his mindset and gave him hope about his cancer. Prior to surgery, he trained to be in the best physical shape possible to prepare for recovery. Long-term, he wanted to walk his daughter down the aisle and complete a full Ironman Triathlon—a 2.4-mile swim, 112-mile bike ride, and a 26.2-mile run, all in one day!

Surgery went well, and Tom is still NED (“no evidence of disease”). He did experience side effects: incontinence, erectile dysfunction, and “the thing that no one likes to talk about: depression.” Joining prostate cancer support groups and sharing his story with other participants proved vital to his mental recovery. Six months after surgery, he completed a half-distance Ironman.

Everyone's goals are different, Tom notes: "It doesn't have to be a triathlon. For some people, the goal might be getting off the couch and walking around the block."


Paying it forward

Having battled both prostate cancer and heart disease, Tom now works tirelessly to show other men that they don't have to struggle alone. "I've met so many men over the last few years that have suffered in silence," he says. "Don't keep those emotions bottled up inside. Seek help. Seek a support group." At certain races, Tom shares his story at a booth or as a featured panelist. All proceeds from his book, *The Winning Mindset That Saved My Life*, go to philanthropic organizations.

A focus on wellness

Tom has been active all his life and encourages others to maintain an active lifestyle to help themselves overcome barriers—whatever 'active' means for their health situation. Age and health challenges have made Tom more intentional about his training and nutrition. He focuses less on race times and more on "the victory of getting to the starting line," and he carefully plans his training to include rest and recovery. His diet also has evolved over the years. He now chooses to avoid red meat, fried foods, high-sugar foods, and dairy, leaving plenty of room for whole grains, fruit and vegetables, and seafood.

See more of Tom's story on [Prostate Cancer Patient Voices](#) and at tomhulsey.com.



Another Year Around the Bases for the 2023 Home Run Challenge!



2023 marked Major League Baseball (MLB) and PCF's 28th season partnering in the Home Run Challenge to support prostate cancer research. During this annual campaign, PCF supporters pledge a donation for every MLB home run hit between June 1st and Father's Day.

During the 2023 Home Run Challenge campaign, nearly 500 donors contributed and 927 home runs were hit, raising more than \$2 million to support prostate cancer research. The Home Run Challenge has raised over \$70 million for prostate cancer research funding since 1996 while increasing national awareness about the benefits of screening and early detection.


Although MLB teams battle each other on the field, all 30 teams join the Home Run Challenge every year. The MLB-PCF Home Run Challenge encourages everyone to join the fight against prostate cancer through America's national pastime — baseball!



PCF Webinar Series 2023-24

For Patients & Caregivers

PCF produces a series of monthly webinars to connect patients and caregivers with the most current, essential information across the various stages of the prostate cancer journey.




Advanced Prostate Cancer - mHSPC
Drs. Oliver Sartor and Neal Shore



Clinical Trials: Overcoming Barriers
Drs. Isla Garraway and Samuel Washington III



Prostate Cancer Disparities: What Men Need to Know
Drs. John Carpten and Stanley Frencher



Advanced Prostate Cancer - mCRPC
Drs. Rana McKay and Mary-ellen Taplin

Each month, PCF hosts interviews with clinicians, investigators, and other leaders in the field of prostate cancer diagnosis, treatment, research, and survivorship. Audience questions are incorporated into the discussion during each live webinar. All videos are later endured on our website, free of charge, for later viewing.

Previous topics of discussion have included:

- Physical and mental wellness
- Managing sexual health and incontinence
- Rising PSA after treatment of localized disease
- Advanced prostate cancer: mCRPC and mHSPC
- When to consider a clinical trial

PCF has hosted approximately 10,000 registrants, and thousands more have viewed our enduring video content.

Please visit pcf.org/pcf-webinar-series to learn more.

Bravo on a superb webinar! The presentations were packed with information and honest in addressing two very important topics to address quality of life. And many thanks to the host for guiding the conversations and posing in-depth, insightful questions.

-Bill M.

Excellent! Thanks for the information provided. Very valuable work.

-Greisha O.

*Thank you very much!
Excellent presentation!*

-Patrick K.


Patient Highlights




Steve Sakakini

"Perhaps the downside of being an engineer is that you can overanalyze what's wrong with you," says Steve. But that skepticism and drive to research his condition ultimately led him to what may prove to be life-extending care. Steve's doctor, PCF-funded investigator Dr. Matthew Rettig, recommended that he undergo intensified 'triplet' treatment.

Diagnosed with metastatic prostate cancer in 2013, Jeff was treated with abiraterone, had an excellent response, and continues to do well off medication: "Not only did I see my girls graduate high school, but they both graduated college, one [received] a master's degree, and one of my daughters just got married! When they were in high school, we didn't even know if I would make it to their graduation. I'm so fortunate!"



Jeff Finerman



Rey Sotelo


Rey and his friend Dave Tozer, having both experienced prostate cancer, started the HOPE Motorcycle Rally to raise awareness about the disease as well as funds for PCF. Rey explains, "I see motorcycles as a catalyst to bring people together, but it's much more than that. The awareness piece is crucial, because men don't talk about [prostate cancer]." Sadly, Dave has since passed away, but his mission lives on—and the Rally continues to take place every year.

Based on PCF-funded research, Eisenmann was treated with pembrolizumab and had an exceptional response. "The Prostate Cancer Foundation saved my life," he says. "Dr. [Dana] Rathkopf saved my life. My wife and my family saved my life. I'm the beneficiary of all that, and I'm the luckiest person in the world."



Stephen Eisenmann

Patient Community & Educational Initiatives



Patient Guides

Localized and Advanced Disease Patient Guides

In 2023, PCF worked with leading clinicians and researchers to produce two new patient guides, one on Localized Prostate Cancer and one on Advanced Disease.

PCF Run/Walk Challenges

PCF Facebook Fundraising Community

In 2024, PCF held its 4th Annual 100 Miles in March Run/Walk Challenge and will hold its 3rd Annual 108 Miles Run/Walk Challenge in September to raise awareness and funds for prostate cancer research.

During Run/Walk Challenges, caregivers, survivors, family, and friends join together in the fight to eradicate prostate cancer. Since 2020, the PCF Facebook fundraising community has raised over \$1.6 million dollars to advance prostate cancer research and reduce death and suffering from this disease.



Live Events

PCF Patient Summits

Launched in 2022, our patient summit initiative aims to bridge the gap between clinicians and patients in the fight against prostate cancer. Open to the public, and with a particular emphasis on patients and minority populations, these events serve three primary objectives: to **increase awareness** of existing and new prostate cancer treatments and resources, **facilitate discussions** on health disparities research specific to prostate cancer, and **foster meaningful dialogue** between the community and leading prostate cancer clinicians and researchers.

In 2023, with support from pharmaceutical funders, we raised **over \$300,000** to hold patient summits at Northwestern University, Moffitt Cancer Center, and Medical College of Wisconsin.

Prostate Cancer Patient Voices

A Patient Testimonial Website in Partnership with PCF



Navigate your prostate cancer journey, your way.

WHO WE ARE

Prostate Cancer Patient Voices is a patient-centered website dedicated to providing support, education, and advocacy for those affected by prostate cancer. We believe that by providing accurate and up-to-date information, we can help men and their loved ones navigate the often-confusing landscape of prostate cancer treatment and education. Our website offers a variety of resources and support, including information on early detection and risk factors, patients sharing their journeys, and in-depth education on how to navigate a prostate cancer diagnosis—from first detection of elevated PSA to ways to live well with the disease.

OUR MISSION

Advancing prostate cancer awareness and support by educational resources and the sharing of collective experiences.

OUR VISION

We envision a society where prostate cancer is no longer a threat to men's health and well-being. Through education, awareness, and early detection, we aim to empower men to take control of their health and create a future where prostate cancer is a manageable and treatable disease.

Patient & Caregiver Storytelling Matters



Don't sit down and let it get you. Know that you are still strong. It's more mental than anything. Be around positive people.

“ Rickey Lee



We had the biopsy, and I remember very clearly it was 12 snips of my life that I could never get back. It was very interesting, to say the least.

“ Baretta Lee



I remember my wife looked at the surgeon and said, 'I want him here to be with me and our 11-year-old daughter for as long as he can.'

“ Henry Cornelius



It is so important to educate yourself and keep asking questions and make sure that you're on the right path for treatment.

“ Staci Cornelius



I was relentless. It was my life, it was my two daughters, it was my wife, it was my sisters and my family. I wasn't going to back down.

“ Michael Salvatore, Jr.



I told my wife, and my wife and I agreed it's not the end of the world. It's another journey that we are going on.

“ Bennie Johnson, Jr.

PCF's Mission to Improve Health Equity

01 Breaking News: PCF Prostate Cancer Screening Guidelines for Black Men in the U.S.

Black men in the U.S. face alarming disparities in prostate cancer diagnosis, disease severity, and mortality compared with other demographic groups. Despite this, Black men have been sidelined by most prostate cancer screening guidelines. To tackle this inequity, PCF convened an expert panel whose tireless efforts led to the first stand-alone prostate cancer screening guidelines for Black men in the U.S. Published in 2024, the guidelines recommend that Black men who elect PSA screening start at age 40-45, and that annual screening be strongly considered from then on depending on an individual's PSA levels and health status.



PCF deeply appreciates the panel's dedication to narrowing this gap in healthcare access and knowledge. At the same time, we recognize that achieving true health equity will require sustained efforts to improve education and access to care and surmount underlying disparities in social determinants of health. PCF stands in solidarity with Black men. We are committed to dismantling barriers and ensuring equitable prostate health outcomes for all.

02 A Conversation with Mike Milken and Isla Garraway

The critical need for these guidelines was highlighted by a January 2023 conversation in which PCF Founder Mike Milken, Dr. Isla Garraway, and Dr. Kneeland Youngblood discussed persistent health disparities and alarming prostate cancer trends in the U.S. In particular, they noted a recent large study¹ showing that new prostate cancer diagnoses rose 3% during 2014-2019, reversing a decades-long trend. The study also found that Black men in the U.S. face a 70% greater risk of prostate cancer and a two to four-fold higher rate of prostate cancer mortality compared with white men. This conversation helped spur PCF's expert panel that generated these much-needed guidelines.



¹Schafer et al. Disparities and trends in genitourinary cancer incidence and mortality in the USA. Eur Urol 2023;84:117-26.

03 PCF Has Received Over \$4.5 Million in Gifts from Philanthropist Robert F. Smith To Tackle Health Inequities

Noted philanthropist Robert F. Smith is an avid PCF supporter who has contributed nearly \$4.5 million to help pave the way for research on ways to detect prostate cancer earlier, especially in Black men. Smith's donations have provided critical support for treatment centers such as the Robert Frederick Smith Precision Oncology Center of Excellence at the Jesse Brown VA Medical Center in Chicago, and for the Smith Polygenic Risk Test, a genetics-based test for early prostate cancer that is expected to be especially helpful for Black men. These funds honor the spirit of Dr. Martin Luther King Jr.'s legacy and represent one of the largest donations ever dedicated for advancing revolutionary prostate cancer research and treatment for Black men.



Robert F. Smith
Founder, Chairman, and CEO
of Vista Equity Partners

"I am delighted to support the life-saving work of accelerating promising medical research to serve our nation's veterans who urgently need better treatments and cures and access to cutting-edge precision oncology. With these resources, we will do right by those brave veterans who served our country, and we will change the odds for millions of African-American men who should be surviving prostate cancer."

- Robert F. Smith

04 Know Your Risk Campaign



In February 2023, PCF launched the 'Black Men: Know Your Risk' campaign, a health equity initiative to raise awareness about prostate cancer and the vital importance of early detection and screening for minority communities.

This campaign aims to provide a wealth of educational resources that empower men to take charge of their health, such as information guides, patient interviews, virtual webinars led by leading experts on prostate cancer disparities, a public service announcement featuring celebrities such as Steve Harvey, Charlamagne tha God, Cedric the Entertainer, and Chris Tucker, and free awareness kits to help Black men understand their risk for prostate cancer and the importance of screening and early detection.

A few of our leading experts participating in this campaign include Dr. Leanne Burnham, Dr. Kosj Yamoah, Dr. John Carpten, Dr. Stan Frencher, Dr. Isla Garraway, and Dr. Michael LeNoir.

Five Reasons to Invest in the Prostate Cancer Foundation

1

Achieve Efficient Results



Christopher Logothetis, MD
MD Anderson Cancer Center

“The reach of PCF is remarkably broad, and it changes everything it touches. The grant application process, for instance, requires precisely 10 pages instead of the typical, daunting 100-page document, and instead of waiting months for an answer and years for funding, PCF promises a quick decision and funding within 90 days. This sets the tone for how PCF gets things done: radically, if need be, and unusually effectively. There’s not a significant advance in the prostate cancer field—not a new drug, not one in the pipeline, not a breakthrough discovery by any researcher or institution—that doesn’t somehow have PCF fingerprints on it. This is what happens when an organization is determined to extract the best possible results from every penny it receives.”

2

Create A Community of Hope




Heather Cheng, MD, PhD
University of Washington
Fred Hutchinson Cancer Research Center

“The Prostate Cancer Foundation has created and nurtured an unparalleled community of patients, families, researchers, doctors, and advocates directed toward a shared passion to save lives from prostate cancer. Their substantial yet nimble support for the best multi-institutional and multi-national researchers in the world directed toward the most urgent clinical questions is clinically relevant to patients and families. The result is an inspiring community of hope with global reach that fuels progress with maximum impact.”

3

Unleash Research Creativity



June Chan, ScD

University of California, San Francisco

“The Prostate Cancer Foundation’s unique funding mechanism has helped researchers pursue their work more creatively and less beholden to paperwork and financial worries that would otherwise sap their concentration, energy, and time. The Foundation frees me to pursue independent novel research projects while at the same time establishing a diverse network of collaborative human capital.”

4

Raise Awareness & Attract Funding



Karen Knudsen, PhD

President / CEO

The American Cancer Society

“The PCF community goes far beyond direct support of transformative research, and the return on investment has been remarkable. PCF has been ‘the’ leader in raising international awareness about prostate cancer risk, screening, and management. As a result, patients are better informed, community physicians have access to the latest findings, and researchers across the world have been connected to speed the pace of discovery. Moreover, seed funding from PCF has allowed prostate cancer researchers to take bold new steps that lay the foundation to acquire the major national funding needed to convert discoveries into patient benefit.”

5


Save Lives



Kenneth Pienta, MD
Johns Hopkins University

“Pretty much every major discovery that has made a difference in helping people live longer, and in fighting lethal prostate cancer, over the last 20 years, can be traced to PCF—either dollars, or advocacy.”

Why Your Investment Matters: Fewer Men Are Dying



We’ve made demonstrable progress in reducing the death rate from prostate cancer. The number of U.S. prostate cancer deaths in 1993—about 40,000—was once expected to rise with the growing number of baby boomer men reaching age 60 and entering the most vulnerable age bracket. Instead of rising, however, the number has dropped by 52%.

Harnessing Relationships and Passion to Fund Crucial Research

New York City, NY

New York Dinner

PCF's annual New York Dinner at the Daniel restaurant featured a special menu by celebrated chef Daniel Boulud and provided an intimate setting to highlight PCF's work. The event, which included a special performance by Grammy Award-winning rock group Train, raised more than \$2 million to help fund PCF's Team Science Challenge Awards and Young Investigator Awards.



New York City, NY

Hamptons Weekend

PCF's annual Hamptons Gala Weekend and Pro-Am event features professional and amateur tennis tournaments and has drawn hundreds of participants and thousands of attendees in its nearly 25-year history. The 2023 Hamptons weekend featured tennis on private courts, salon dialogues on key topics, and a Friday night gala at the Parrish Art Museum that included a performance by Adam Lambert. Recognized as one of the top five summer events in the area, the event raised \$4 million for prostate cancer research.




Harnessing Relationships and Passion to Fund Crucial Research

Palm Beach, FL

South Florida Dialogues



In February 2024, PCF held its annual Milken Institute South Florida Dialogues with the Pro-Am Tennis & Golf Tournament in South Florida. The five-day event featured discussions, tennis matches, and a Gala Dinner at the historic Henry Morrison Flagler Museum. Honorees included John and Daria Becker Barry, and performers included Oz Pearlman and Pat Benatar and Neil Giraldo. The funds raised will aid PCF's initiatives in prostate cancer research and support young investigators and care for U.S. veterans.



Palm Springs, CA

Indian Wells Event

Following last year's successful event at The Indian Wells Tennis Garden in 2023, we hosted our annual tennis event in March 2024. In addition to engaging tennis sessions, the weekend-long event featured an inspiring evening with tennis legends who together have earned 16 grand slam titles, plus a fireside chat with PCF Founder and Chairman Michael Milken, who highlighted 5 decades of medical research and public health advances and their impact on future healthcare.





AUDIT
AND
ASSURANCE

INDEPENDENT AUDITOR'S REPORT

To the Board of Directors
Prostate Cancer Foundation

Report on the Audit of the Financial Statements

Opinion

We have audited the consolidated financial statements of Prostate Cancer Foundation, which comprise the consolidated statement of financial position as of December 31, 2023, and the related consolidated statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the consolidated financial statements.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of Prostate Cancer Foundation as of December 31, 2023, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of Prostate Cancer Foundation and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Prostate Cancer Foundation's ability to continue as a going concern for one year after the date that the consolidated financial statements are issued.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists.

The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

To The Board of The Directors
Prostate Cancer Foundation

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Prostate Cancer Foundation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Prostate Cancer Foundation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Report on Summarized Comparative Information

We have previously audited Prostate Cancer Foundation's December 31, 2022 consolidated financial statements, and we expressed an unmodified audit opinion on those audited consolidated financial statements in our report dated August 14, 2023. In our opinion, the summarized comparative information presented herein as of and for the year ended December 31, 2022, is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived.

Green Hasson & Janks LLP

August 12, 2024
Los Angeles, California

PROSTATE CANCER FOUNDATION

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

December 31, 2023

With Summarized Totals at December 31, 2022

	Without Donor Restrictions	With Donor Restrictions	2023 Total	2022 Total
ASSETS				
Cash and Cash Equivalents	\$ 50,906,155	\$ -	\$ 50,906,155	\$ 35,502,698
Investments	701,140	-	701,140	6,858,888
Pledges Receivable (Net)	29,616,302	6,335,412	35,951,714	39,819,845
Prepaid Expenses and Other Assets	543,772	-	543,772	338,011
Right-of-Use Asset	548,076	-	548,076	1,096,151
Property and Equipment (Net)	480,202	-	480,202	623,868
Intangible Assets	2,754,862	-	2,754,862	3,068,300
TOTAL ASSETS	\$ 85,550,509	\$ 6,335,412	\$ 91,885,921	\$ 87,307,761
LIABILITIES AND NET ASSETS				
LIABILITIES:				
Accounts Payable	\$ 399,800	\$ -	\$ 399,800	\$ 1,018,666
Accrued Liabilities	1,768,080	-	1,768,080	2,158,323
Grants Payable (Net)	39,330,540	-	39,330,540	35,949,555
Lease Liability	550,760	-	550,760	1,096,151
Note Payable	1,739,373	-	1,739,373	1,687,500
TOTAL LIABILITIES	43,788,553	-	43,788,553	41,910,195
NET ASSETS:				
Without Donor Restrictions	41,761,956	-	41,761,956	27,569,232
With Donor Restrictions	-	6,335,412	6,335,412	17,828,334
TOTAL NET ASSETS	41,761,956	6,335,412	48,097,368	45,397,566
TOTAL LIABILITIES AND NET ASSETS	\$ 85,550,509	\$ 6,335,412	\$ 91,885,921	\$ 87,307,761

PROSTATE CANCER FOUNDATION

CONSOLIDATED STATEMENT OF ACTIVITIES

Year Ended December 31, 2023

With Summarized Totals for the Year Ended December 31, 2022

	Without Donor Restrictions	With Donor Restrictions	2023 Total	2022 Total
REVENUE, PUBLIC SUPPORT AND OTHER INCOME				
Grants and Contributions	\$ 45,348,480	\$ 6,335,412	\$ 51,683,892	\$ 66,692,388
Sponsorships	3,652,000	-	3,652,000	5,122,375
Interest and Other Income	2,435,259	-	2,435,259	470,395
Net Assets Released from Donor Restrictions	17,828,334	(17,828,334)	-	-
TOTAL REVENUE, PUBLIC SUPPORT AND OTHER INCOME	69,264,073	(11,492,922)	57,771,151	72,285,158
EXPENSES:				
Program Services	45,458,352	-	45,458,352	49,793,252
Supporting Services:				
Management and General	4,434,981	-	4,434,981	5,049,079
Fundraising	5,178,016	-	5,178,016	6,364,953
TOTAL EXPENSES	55,071,349	-	55,071,349	61,207,284
CHANGE IN NET ASSETS	14,192,724	(11,492,922)	2,699,802	11,077,874
Net Assets - Beginning of Year	27,569,232	17,828,334	45,397,566	34,319,692
NET ASSETS - END OF YEAR	\$ 41,761,956	\$ 6,335,412	\$ 48,097,368	\$ 45,397,566

PROSTATE CANCER FOUNDATION

CONSOLIDATED STATEMENT OF FUNCTIONAL EXPENSES

Year Ended December 31, 2023

With Summarized Totals for the Year Ended December 31, 2022

	Program Services				Total Program Services
	Research Grants	Scientific Conferences and Programs	Public Awareness	Health Care Provider Education	
Research Grants	\$ 29,321,704	\$ -	\$ -	\$ -	\$ 29,321,704
Compensation, Benefits and Payroll Taxes	-	2,962,263	2,712,010	1,175,041	6,849,314
Outreach, Events and Meetings	-	-	2,429,239	1,698,020	4,127,259
Global Scientific Conferences, Conventions and Meetings	-	2,277,823	-	-	2,277,823
Office Expenses and Other	-	131,472	186,331	-	317,803
Professional Fees	-	179,804	308,906	-	488,710
Travel, Meals and Entertainment	-	51,624	277,676	-	329,300
Media, Public Relations and Publications	-	-	1,027,991	-	1,027,991
Occupancy	-	103,488	199,280	-	302,768
Depreciation and Amortization	-	26,056	389,624	-	415,680
TOTAL 2023 FUNCTIONAL EXPENSES	\$ 29,321,704	\$ 5,732,530	\$ 7,531,057	\$ 2,873,061	\$ 45,458,352
					83%
TOTAL 2022 FUNCTIONAL EXPENSES	\$ 36,455,898	\$ 4,452,381	\$ 5,748,581	\$ 3,136,392	\$ 49,793,252
					81%

	Supporting Services			Total Expenses	
	Management and General	Fundraising	Total Supporting Services	2023	2022
Research Grants	\$ -	\$ -	\$ -	\$ 29,321,704	\$ 36,455,898
Compensation, Benefits and Payroll Taxes	2,091,961	1,386,889	3,478,850	10,328,164	9,222,524
Outreach, Events and Meetings	-	1,783,442	1,783,442	5,910,701	7,320,409
Global Scientific Conferences, Conventions and Meetings	4,078	-	4,078	2,281,901	2,205,419
Office Expenses and Other	914,762	892,829	1,807,591	2,125,394	1,766,745
Professional Fees	851,824	350,039	1,201,863	1,690,573	1,527,990
Travel, Meals and Entertainment	252,224	675,174	927,398	1,256,698	1,044,238
Media, Public Relations and Publications	26,507	-	26,507	1,054,498	571,190
Occupancy	229,382	71,812	301,194	603,962	602,171
Depreciation and Amortization	64,243	17,831	82,074	497,754	490,700
TOTAL 2023 FUNCTIONAL EXPENSES	\$ 4,434,981	\$ 5,178,016	\$ 9,612,997	\$ 55,071,349	
	8%	9%		100%	
TOTAL 2022 FUNCTIONAL EXPENSES	\$ 5,049,079	\$ 6,364,953	\$ 11,414,032		\$ 61,207,284
	9%	10%			100%

PROSTATE CANCER FOUNDATION

CONSOLIDATED STATEMENT OF CASH FLOWS

Year Ended December 31, 2023

With Summarized Totals for the Year Ended December 31, 2022

	2023	2022
CASH FLOWS FROM OPERATING ACTIVITIES:		
Change in Net Assets	\$ 2,699,802	\$ 11,077,874
Adjustments to Reconcile Change in Net Assets to Net Cash Provided By Operating Activities:		
Change in Allowance for Doubtful Pledges Receivable	120,000	358,000
Change in Present Value Discount on Pledges Receivable	(1,182,990)	1,124,072
Depreciation and Amortization	497,754	490,700
(Increase) Decrease in:		
Pledges Receivable	4,931,121	(21,691,202)
Prepaid Expenses and Other Assets	(205,761)	(108,153)
Right-of-Use Asset	548,075	540,074
Increase (Decrease) in:		
Accounts Payable	(618,866)	295,071
Accrued Liabilities	(390,243)	401,527
Grants Payable	3,380,985	12,720,108
Lease Liability	(545,391)	(540,074)
	9,234,486	4,667,997
NET CASH PROVIDED BY OPERATING ACTIVITIES		
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchase of Intangible Assets	(40,650)	(39,600)
Proceeds on Sale of Investments	6,858,888	-
Purchase of Investments	(701,140)	(6,858,888)
	6,117,098	(6,898,488)
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES		
CASH FLOWS FROM FINANCING ACTIVITIES:		
Borrowing on Note Payable	51,873	-
Repayment of Note Payable	-	(843,750)
	51,873	(843,750)
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES		
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	15,403,457	(3,074,241)
Cash and Cash Equivalents - Beginning of Year	35,502,698	38,576,939
CASH AND CASH EQUIVALENTS - END OF YEAR	\$ 50,906,155	\$ 35,502,698
SUPPLEMENTAL SCHEDULE OF NON-CASH OPERATING ACTIVITIES:		
Non-Cash Impact of Implementation of Accounting Standards Update No. 2016-02, <i>Leases (Topic 842)</i>		
Establishment of Right of Use Asset	\$ -	\$ 1,636,225
Establishment of Lease Liability	-	1,636,225

Board of Directors & Executive Leadership

Michael Milken

Founder and Chairman
Prostate Cancer Foundation

Kelvin A. Baggett, MD

Internal Medicine Physician

Emilio Bassini

Managing Principal
Bassini & Company

Tricia Berns

Michael & Tricia Berns
Philanthropy

Gregory Q. Brown

Chairman & CEO
Motorola Solutions, Inc.

Steven A. Burd

Founder and CEO
Burd Health, LLC

Josh Cohen

Founder and Partner
City Light Capital

Neil P. DeFeo

Executive Partner
Nonantum Capital Partners

David A. Ederer

Chairman
Ederer Investment Company

Jonathan Evans

President
Evans & Co., LLC

R. Christian B. Evensen

Managing Partner
Flintridge Capital
Investments, LLC

Ralph Finerman

Chief Financial Officer,
Treasurer and Secretary

Peter T. Grauer

Chairman
Bloomberg LP

The Reverend Rosey Grier

Consultant
Milken Family Foundation

Stuart Holden, MD

Clinical Professor of Urology
David Geffen School of Medicine,
Spielberg Family Chair of Urologic
Oncology,
Associate Director, UCLA Institute
of Urologic Oncology

Philip Kantoff, MD

Co-Founder and CEO
Convergent Therapeutics, Inc.

Freda Lewis-Hall, MD

Managing Director
IntelMed, LLC

The Honorable Earle I. Mack

Senior Partner
The Mack Company

Shmuel Meitar

Chairman and Founder
Aurec Capital

Lori Milken

Vice President
Prostate Cancer Foundation

Michael Muldowney

Chief Executive Officer
Foxford Capital LLC

Henry L. Nordhoff

Chairman and CEO
Banyan Biomarkers, Inc.

Drew Pinsky, MD

Internist, Addictionologist,
Radio and Television Host

Neal I. Rodin

Chairman
International Financial Company, LLC
Managing Director
RREI, LLC

Jason J. Safriet

Managing Director
Head of Security Sales
Credit Suisse

Richard V. Sandler

Partner
Maron & Sandler
Executive Vice President
Milken Family Foundation

Keith B. Shoates

Vice President, Office of the CEO
Vista Equity Partners

Howard Shore

Executive Chairman
Shore Capital Group

Jonathan W. Simons, MD

Chief Science Officer
Marcus Foundation

David Taglight

Chairman
The John Black Charitable
Foundation

Vincent J. "Vinnie" Viola

Chairman, Owner, and Governor
Florida Panthers Hockey Club,
Sunrise Sports and Entertainment,
The BB&T Center and SSE
Additional Operating Entities

Kneeland Youngblood, MD

Founding Partner
Pharos Capital Group

Jeff Zisk

Managing Director
Surrey Ventures



30 YEARS OF PROGRESS

PROSTATE CANCER FOUNDATION



CURING TOGETHER

EACH HOME RUN HIT TODAY
WILL RAISE AN ADDITIONAL
\$50,000
FOR PROSTATE CANCER RESEARCH

CHANGING THE WORLD & CURING TOGETHER

“You are not your
body because
one day it will fail.
You are the spirit
underneath.”
– Dr. Russell Clayton,
survivor



facebook.com/PCF.org



@PCFnews

1250 Fourth Street, Santa Monica, CA 90401 | 800.757.CURE (2873) | www.pcf.org